WebTalazoparib (BMN-673) 是一种高效的,具有口服活性的 PARP 1/2 抑制剂。Talazoparib 抑制 PARP1 和 PARP2 酶活性的 Ki 值分别为 1.2 nM 和 0.87 nM。Talazoparib ... data suggest that the GI effects observed in the cisplatin and BMN 673 treatment arms are due to the anti-proliferative effects of these ... WebApr 11, 2024 · Two PARP inhibitors, Talazoparib and Olaparib, were approved by the FDA in 2024 for patients who have advanced HER2 negative breast cancer and a germline BRCA …
Talazoparib - Oral Patient Medicine Information MIMS Singapore
WebFeb 1, 2024 · More common Belching change or loss of taste decreased appetite diarrhea dizziness headache heartburn indigestion nausea stomach discomfort, upset, or pain thinning or loss of hair vomiting WebDo not take an extra dose to make up for a missed dose. If you take too much TALZENNA, call your healthcare provider or go to the nearest hospital emergency room right away. … cc at bottom of formal letter
TALAPRO-2 Supports First-Line Talazoparib/Enzalutamide in All …
WebJun 11, 2024 · Overall, Dr. Sartor explained, there aren’t notable differences in the types or severity of the side effects caused by olaparib and rucaparib. And although most patients … WebFeb 2, 2024 · Talazoparib is contraindicated during breastfeeding. The manufacturer states that breastfeeding is not recommended during talazoparib treatment and for at least one … WebBrief Summary: This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy. bus shefford to biggleswade